SynthesisBMC cardiovascular disorders2025
The effect of exosome-related therapy in cardiac revascularization procedures: a systematic review.
Synthesis in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular diseases (CVDs) remain the leading global cause of mortality despite advances in revascularization strategies like coronary artery bypass grafting (CABG) and percutaneous interventions. Exosomes have emerged as dual-function agents, acting both as paracrine mediators of vascular repair and as drug-delivery vehicles. This systematic review evaluates the therapeutic efficacy of exosome-based therapies in cardiac revascularization procedures.
methodsA comprehensive search of Embase, PubMed, Scopus, and Web of Science was conducted from inception to January 2025. We included experimental studies, evaluating animal subjects undergoing revascularizations. Risk of bias was assessed using SYRCLE’s tool. Study characteristics, population characteristics, intervention details, various outcomes, and limitations of each study were extracted from each included study.
resultsEight preclinical studies met our inclusion criteria. We observed that exosome therapies demonstrated significant benefits. Sirolimus-loaded exosomes (SIR-EXO) reduced stenosis to 5% vs. 59% in controls. Exosome-coated stents (ACC-Exo-REDV) suppressed neointimal hyperplasia by 60% compared to bare stents. Brown adipose tissue-derived exosomes increased left ventricular ejection fraction, while CABG + exosome patches restored diastolic function. Exosome-eluting stents reduced pro-inflammatory cytokines (IL-1β, TNF-α) by 93% and promoted M2 macrophage polarization. Exosome-enhanced stents improved endothelial cell proliferation by 40% and reduced platelet adhesion by 70%.
conclusionExosome-based therapies show promise in enhancing vascular repair, mitigating restenosis, and modulating post-revascularization inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.